文献速递妇科

解旋酶POLQ样蛋白(HELQ)作为上皮性卵巢癌铂类化疗耐药的新指标

Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-03-21

该研究探讨HELQ在上皮性卵巢癌化疗耐药中的作用,对87例患者行免疫组化及生存分析,并分析TCGA数据集,在OVCAR3和A2780细胞系中行过表达和敲低实验。结果显示HELQ表达与铂类化疗反应及总生存、无病生存相关,HELQ过表达增加而敲低降低细胞对顺铂的耐药性、DNA修复活性及核苷酸切除修复(NER)通路DNA修复蛋白表达。作者认为HELQ可作为上皮性卵巢癌化疗耐药的新指标并预测预后。

要点

  • HELQ表达与上皮性卵巢癌患者铂类化疗反应、总生存和无病生存相关。
  • HELQ过表达增加细胞对顺铂的耐药性和DNA修复活性。
  • HELQ敲低降低细胞对顺铂的耐药性、DNA修复活性及NER通路修复蛋白表达。

核心结论

  • HELQ通过调控核苷酸切除修复(NER)通路DNA修复蛋白表达,影响细胞对顺铂的反应及患者对铂类化疗的反应。
  • 作者认为HELQ可作为上皮性卵巢癌化疗耐药的新指标,并可预测该病预后。

研究设计与样本

  • 对87例上皮性卵巢癌患者行免疫组化及生存分析,并分析TCGA数据集。
  • 采用定量逆转录聚合酶链反应(qRT-PCR)和Western Blot分析上皮性卵巢癌组织以确认HELQ表达。
  • 在OVCAR3细胞系中行HELQ过表达、在A2780细胞系中行RNA干扰敲低,用CCK8法测定细胞对顺铂的反应。
  • 采用宿主细胞再激活试验评估细胞DNA修复能力,用Western Blot分析HELQ对DNA修复基因的影响。

主要发现

  • HELQ表达与上皮性卵巢癌患者对铂类化疗的反应、总生存(OS)和无病生存(DFS)相关。
  • HELQ过表达增加细胞对顺铂的耐药性、DNA修复活性及核苷酸切除修复(NER)通路DNA修复蛋白表达。
  • HELQ敲低降低细胞对顺铂的耐药性、DNA修复活性及核苷酸切除修复(NER)通路DNA修复蛋白表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the role of HELQ in chemo-resistance of epithelial ovarian carcinoma (EOC), which is a critical factor of patients' prognosis. METHODS: Immunohistochemistry, survival analysis of our 87 EOC patients and bioinformatics analysis of The Cancer Genome Atlas (TCGA) datasets (Nature, 2011) disclosed the clinical importance of HELQ expression. Quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western Blot analyses of EOC tissue were used to confirm it. Ectopic overexpression and RNA interference knockdown of HELQ were carried out in OVCAR3 and A2780 cell lines, respectively, to determine the effect of altered HELQ expression on cellular response to cisplatin by CCK8 assay. The DNA repair capacity of these cells was evaluated by using host-cell reactivation assay. Western Blot analyses were carried out to determine the effect of HLEQ on the DNA repair genes by using cells with altered HELQ expression. RESULTS: HELQ expression associates with response of EOC patients to platinum-based chemotherapy and their overall survival (OS), disease free survival (DFS). HELQ overexpression or knockdown, respectively, increased and decreased the cellular resistance to cisplatin, DNA repair activity, and expression of DNA repair proteins of Nucleotide excision repair (NER) pathway. CONCLUSIONS: HELQ plays an important role in regulating the expression of DNA repair proteins NER pathway which, in turn, contributes to cellular response to cisplatin and patients' response to platinum-based chemotherapy. Our results demonstrated that HELQ could serve as a novel indicator for chemo-resistance of EOC, which can predict the prognosis of the disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Long J, Zhu JY, Liu YB, et al. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer. Gynecol Oncol. 2018. PMID: 29572031. doi:10.1016/j.ygyno.2018.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。